Stockreport

Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF -- Data Show High Rates of Response to Single Infusion of KTE-X19 -- -- Phase 2 Portion of ZUMA-3 is Ongoing and Includes Dosing and Revised [Read more]